Neuroimaging Studies

神经影像学研究

• 批准号: 8286422
• 负责人: Francis Joseph McClernon
• 金额: $ 13.24万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8286422
• 关键词: Abstinence; Adult; Amygdaloid structure; Anterior; Behavioral; Blood; Brain; Brain region; Bupropion; Cause of Death; Cerebrovascular Circulation; Cerebrum; Cigarette; Clinical; Clinical Trials; Control Groups; Cues; Data; Development; Functional Magnetic Resonance Imaging; Future; Goals; Image; Infusion procedures; Intervention; Investigation; Measures; Metabolic; Outcome; Participant; Pharmaceutical Preparations; Pharmacotherapy; Placebos; Psychological reinforcement; Randomized; Recruitment Activity; Relapse; Research Personnel; Rosa; Sampling; Scanning; Screening procedure; Smoke; Smoker; Smoking; Structure; TNFRSF5 gene; Techniques; Time; Withdrawal; Withholding Treatment; Work; addiction; arm; base; cigarette smoking; cingulate gyrus; cue reactivity; design; disability; effective therapy; experience; improved; insight; interest; neuroimaging; neuromechanism; nicotine patch; nicotine replacement; preclinical study; randomized trial; relating to nervous system; response; smoking cessation; smoking relapse; success; therapy design; treatment effect; treatment response; treatment strategy; varenicline

The primary aim of the proposed center is to develop and evaluate pre-cessafion adapfive treatments for cigarette addiction. The overarching goal of this project is to evaluate the neural mechanisms that underiie pre-cessation medication effects. In a design paralleling Project 1. Clinical Trials (PD: Rose), 100 smokers will be assigned to one of four treatment arms. In all four arms, participants will confinue to smoke their usual brand of cigarettes in the two weeks prior to quitting smoking. The control (CNTRL) group will wear a placebo patch in the two weeks prior to their quit date. A second group will wear a 21 mg/d patch for the two weeks prior to the quit date (NRT-Only). A third group will switch from wearing a nicotine patch to taking varenicline in the second week (NRT¿¿VAR). A fourth group will take bupropion SR in addition to NRT in the second week (NRT+BUP). Participants will be scanned at tiaseline and again 12 hrs after quitting smoking. During scanning, we will measure brain reactivity to smoking cues and cerebral blood fiow. Common and unique effects of pre-cessation pharmacotherapies will be identified. Based on preliminary data, we hypothesize that pre-cessation treatment will result in lower brain reactivity to smoking cues and cerebral blood flow following quitfing smoking. We also hypothesize that baseline brain funcfion will be predictive of pre- and post-quit treatment response. The proposed project builds upon the investigative team's experience and is highly integrated with the center's other projects and cores.

拟议中心的主要目的是开发和评估香烟成瘾的切尔德治疗方法。该项目的总体目标是评估未经筛选药物效应的神经机制。在平行的设计1.临床试验（PD：Rose）中，将有100名吸烟者分配到四个治疗臂之一。在所有四个武器中，参与者都将在戒烟前的两周内仅限于吸烟。对照组（CNTRL）组将在退出日期之前的两周内穿安慰剂补丁。第二组将在退出日期之前的两周内穿21 mg/d的补丁。第三组将从尼古丁补丁转变为第二周（NRT¿VAR）服用Varenicline。除了第二周内NRT（NRT+BUP）外，第四组还将服用安非他酮SR。吸烟后将在Tiaseline扫描参与者，并在12小时内进行扫描。 在扫描过程中，我们将测量对吸烟线索和脑血液的大脑反应性。将确定过分娩药物治疗的常见和独特作用。基于初步数据，我们假设戒烟前的诊断治疗将导致大脑对吸烟线索的反应性降低，并在退出吸烟后会导致大脑的反应性和脑血流。我们还假设基线脑功能将预测前后治疗后反应。拟议的项目以调查团队的经验为基础 并与中心的其他项目和核心高度融合。